Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
<Like Dewophile, I'm staying in. I don't know about you but I can't find another $125 M company with a late-stage blockbuster in its pipeline that has close to zero efficacy risk. If anyone has any suggestions I'm listening, because I'm sitting on a bunch of cash in my biotech portfolio in addition to my positions in RPRX, JAV, and NVD.[i/]>
Thanks, I'm still holding strongly, too, like you and dewophile. I am curious now about your thoughts on JAV and NVD! :) Are you willing to outline these companies at all on the Biotech Value forum?
Cheers,
Spartex
<<From the RPRX prospectus, are these timelines what you had anticipated?? I thought March 07 was the anticipated update for these trials. Thoughts? Thanks!>>
RPRX Research & Development Programs
Our product development pipeline is summarized in the table below:
Product Candidate (Indication) Status Next Expected Milestone(s)
Proellex
Uterine Fibroids Phase 2 (U.S.) Full Phase 2 data(mid-2007)
One year extension data (4Q2007)
Initiate pivotal trials (YE2007)
Endometriosis Phase 1/2 (Europe) Full Phase 1/2 data (3Q2007)
Initiate U.S. Phase 2 (mid-2007)
Androxal
Male Secondary Hypogonadism Non-pivotal Phase 3 (U.S.) Full non-pivotal Phase 3 data (3Q2007)
Initiate first pivotal Phase 3 (around YE2007)
http://www.sec.gov/Archives/edgar/data/897075/000095013407000926/h42891b5e424b5.htm#109
RPRX question: Does anyone have a idea on how long it may take for RPRX to make a follow-up announcement regarding pricing for this share offering?
Thanks!
David did you meet with Joe P. (RPRX) at JP Morgan biotech conference? And if so, will you provide an update to your subscribers?
Thanks!
Dew, what was the outcome of the older dispute between IDIX and UAB concerning the milestones and potential royalties
on NM283? Do you think the new filing has much merit based on the past case?
Thanks for your thoughts.
Spartex
Repros executives get pay hike
Houston Business Journal - 3:36 PM CST Friday
The board of directors of Repros Therapeutics Inc. have approved salary increases for CEO Joseph Podolski and Louis Ploth, the firm's chief financial officer, effective Jan. 1.
According to a Securities and Exchange Commission filing submitted Friday, Podolski, also president of The Woodlands-based Repros (NASDAQ: RPRX) will see his annual salary increase by 7 percent to $354,000. Ploth, also vice president of business development, will see his salary bumped to $224,000.
In addition, Podolski and Ploth received options to purchase as many as 50,000 shares and 20,000 shares of the biopharmaceutical firm, respectively, at $12.26 over three years, based on the Jan. 8 closing price, the date of grant.
Trading volume on Repros shares moved slightly higher than normal Friday, boosting the shares by more than 4 percent, or 55 cents, to close at $12.79
http://www.bizjournals.com/houston/stories/2007/01/08/daily56.html?f=et63&hbx=e_du
Yep, now eyeing SGEN. Thanks for your write ups on IDIX and RPRX. Excellent work.
Strong buying interest in RPRX this morning. 12.85
First noticed it yesterday morning on opening which pushed the stock up 50 cents (12.5) and it closed at 12.24. Continued interest today and there aren't many shares for sale, hence the price is moving up.
IDIX is also finally recovering nicely on moderate volume yesterday and a bit this morning.
I agree, too, that IDIX is near a bottom, which is why I started a position last week. Very low volume indicates that most of the earlier selling is finished. Alternatively, the buying has been light.
Looks like a few buyers are coming in today but there isn't a lot of stock for sale. Hence the price has had a little rise. All we need is some stronger buying and IDIX will pop over $9 without hesitation.
I wonder if the benefits of drinking coffee (beneficial organic compounds) are similarly affected by adding milk?
I add milk to my coffee to cut the strength (I make strong coffee). So now I might have to think about keeping out the milk to get the full benefits. Rats.
What were your estimates for Tyzeka / Sebivo sales the first year? JP sounds like he has a terrible cold, coughing and sneezing. Might have been better for someone else to make the presentation? He sounds like he should be home in bed. Just my opinion. If you are trying to appear professional, having a bad cold doesn't enhance your appearance to the listeners.
Do we infer that the selection of Dr. Mayers, who specializes in HIV, that IDIX wants to put more focus on gearing up their HIV clinical trials?? I realize he has a former professional relationship with CEO.
Thanks
Thanks for your thougts on IDIX this coming Tues.
I just started a new IDIX position at 8.6 on Friday. Sold at a 5% in the 11's earlier this year. Been watching it ever since and feel the timing to buy is right. Trimmed back some of my RPRX (gains) to allow this purchase (as I was too focused in that stock). Now own in order of position size (value): REGN (6's and 11 price purchases from '05 and '06), RPRX (6's), DNDN (mid 4's avg), and now IDIX. DNDN has been my DOG. We'll see if it can get out of the cellar this spring.
I was very fortunate with REGN when it got beat up, and then late in 06 with RPRX purchases per rfj's posts. It looks like IDIX's price is pretty much washed out and very attractive for the upcoming year's events. I might buy a little more on Monday.
Best wishes to IDIX longs in '07!
Spartex
Thanks David, and appreciate your efforts in finding out a few more nuggets on RPRX from your discussions with Joe out in SF which you'll report in your newsletter updates.
Cheers,
Spartex
I got turned on just for reporting on the analyst.
LOL. Maybe you need a cold shower and a smoke now?? ;)
Short squeeze on AGIX?? 37% short position. Stock up 18% on volume.
http://finance.yahoo.com/q/ks?s=AGIX
No, I missed that "volume" from the recording! ;)
Seriously though, any feedback regarding my Q would be appeciated. I believe RPRX presents out in San Francisco next week at JP Morgan conf.
Question on attendance at RPRX meeting:
David, could you elaborate on the volume of analysts present at yesterdays RPRX analyst meeting in NYC (if you were there)? It sounded like a good crowd from what I heard in the background prior to the start.
Thanks for sharing!
What do you see on Level 2 for RPRX this morning?
http://finance.yahoo.com/q/bc?s=RPRX&t=1d
It appears they filled a large block of shares up near 12.19, and then took the stock back down to 11.84 to hunt shares on thin volume. Am I misunderstanding the trading action??
TIA
RPRX conspiracy??
1) Schwab notifies me that I can't margin RPRX beyond the 50% level (they normally allow you to margin up to 70% but yeah that is suicide).
2) rfj wasn't allowed into today's RPRX special presentation for analysts.
3) Yahoo's RPRX message board was discontinued (for the moment?)
If this all happened to Dendreon stockholders it would result in a "revolt" on IV message board and probably 100+ postings. ;)
But...you never know if this is just a coincidence or some hedge fund trying to pressure small retail share holders of RPRX. LOL!
You need to subscribe to his newsletter. You can get a 3 month subscription for $150, which allows you to view his archive going back 30 days.
http://www.biotechmonthly.com/latest-issues.htm
David Miller put out a nice 6 page summary after the meeting.
It was very encouraging on the direction the company is going with their trials and results.
Would one expect fibroids to shrink significantly in 12 weeks?
RPRX pre-webcast shows 167 slides. My goodness that is a lot of information! Hopefully not too much.
See y'all later.
RPRX: Do you know how long the presentation will last? And, are the Doctors on the invitation list there to make presentations, or just for Q/A's on the trial results?
Will there be any discussion on raising $$ tomorrow by the company?
That aside, does anyone know if Think Equity or Punk revised their RPRX target prices after the results? Or are they waiting after tomorrow's presentations.
I'll dial in via the web to listen in. Thanks for your updates as always!
Dew, very sorry to hear about the news on Belle. My condolences.
My estimate is for an avg. of 53 posts/day in 2007.
rfj, are you saying that your 10% loss rule applied to your buying of RPRX?
At what price did you first start buying? It would have to have been in early 2006 (Jan-early March) before RPRX ran up to 8+, as it has come all the way back down to the upper $5's where I started to purchase it in mid-Nov (in other words, >10% decline).
Looking forward to your update from analysts' day for RPRX next week. I would think with the stock priced at $13 now, a 2 mil share secondary would raise $22-25 mil. Will that cover the companies plans to complete their trials in 07-08?
Thanks again for your biotech pick list. I'm going to look at your NBIX turnaround for 2007 pick. I like that it has a very large cash position.
Spartex
If David gets on the CNBC segment it won't be until this 3 pm EST hour.
<<you had said that they didn't update their reports with the RPRX new data and I said they did>>
I think you are confusing me with Thomas. I just was curious if Think Equity or Punk would come out with revised targets after stellar reports on interim trials by RPRX. If not this week, definitely after their Jan 4 special "by invitation only" analyst day and presentations.
THanks for any insights.
So Punk and ThinkE will come out next week with their revisions on RPRX price targets??
Thanks!
<<RPRX takeout>> question.
I am using some links to rfj's earlier posts from RPRX yahoo message board. I do have some questions on his views too, as he mentions RPRX as being worth $300-500 mil market cap in Oct (at least where share price should be) before the Dec results, and then after the third trial results this past week he mentions it should at least be $200-250 mil market cap, easy. rfj, did you become a little more cautious?
Ok, here are his links for what he thinks their shares should at least be trading, and then his thoughts on potential sales for their drugs which I believe depend on solid final March results from these trials. To summarize, he believes shares could trade up to the 20-30 range by mid-2007. I'm guessing the company could be sold for $500 mil or better (in parts) depending on final outcome of trials and additional trials needed, or around $50 if there is little share dilution.
http://messages.finance.yahoo.com/Business_%26_Finance/Investments/Stocks_%28A_to_Z%29/Stocks_R/thre....
http://messages.finance.yahoo.com/Business_%26_Finance/Investments/Stocks_%28A_to_Z%29/Stocks_R/thre....
David,
Do you cover RPRX, and if so, for how long?
Edit: I see you do cover RPRX since Feb 06.
http://www.biotechmonthly.com/coverage.htm
I assume you are also very bullish on their trio of results this past week!
Thanks and have a great holiday too!
Spartex
Wow, I was in a meeting the past 45 min. Missed the 8.9 to 9.9 surge! The buyers are were waiting for sellers and they couldn't find any. So they eventually moved their bids up.
Have a great Holiday all and thanks Dew et al. for making this biotech values board a clear "winner"!
Spartex
RPRX taking off. A tiger in the tank. Realization (valuation) is finally occurring.
RPRX- REPROS THERAPEUTICS INC News/Chart Trade 12:12:31 ET, 12/22/2006
Last Trade 8.65 Volume 253,827 Tick -
Change +0.93 Change % +12.05
RPRX inside purchases by new Chief Medical Officer.
Interesting that he had 6000 shares already before RPRX announced his hiring on Dec 18.
INSIDER TRANSACTIONS REPORTED - LAST TWO YEARS
Date Insider Shares Type Transaction Value*
19-Dec-06 VAN AS ANDRE MD, PHD
Officer 2,000 Direct Purchase at $7.08 per share. $14,160
16-Dec-06 VAN AS ANDRE MD, PHD
Officer 6,000 Direct Statement of Ownership N/A
http://finance.yahoo.com/q/it?s=RPRX
Regeneron Signs Lease for New Headquarters Facility to Be Built in Westchester County, NY
Thursday December 21, 4:00 pm ET
TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN - News) today signed a 15-year lease with BioMed Realty Trust, Inc. for a new corporate headquarters and research and development complex to be constructed adjacent to its current facility at the Landmark at Eastview in the Town of Greenburgh in Westchester County, New York. Regeneron also has the option to extend the lease for three additional 5-year periods.
The state-of-the-art complex will consolidate Regeneron's 440 Tarrytown-based employees, currently scattered among six buildings, into a three-building, interconnected campus. The new facilities will include approximately 194,000 square feet of laboratory and office space in two buildings to be constructed by BioMed Realty Trust over the next two years. The Company will also retain its 27,000 square foot specialized VelociGene® research facility in an existing building at the Landmark at Eastview. The new buildings will incorporate energy efficient technologies along with an open and flexible design that will enhance workplace interactions.
"This new, custom-designed facility supports our efforts to position Regeneron for the future. We have in place an ambitious business strategy built around our existing product candidates, robust scientific research programs, and an antibody technology platform that we intend to use to expand our clinical pipeline. The generous incentives we have received from New York State, the Town of Greenburgh, and the Westchester County IDA allow us to remain in our current location in Westchester County, NY. Further, the new facility will incorporate efficient design features and technologies that will enhance our business operations and provide cost-efficiencies," stated Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.
About Regeneron
Regeneron is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of cancer, eye diseases, and inflammatory diseases and has preclinical programs in other diseases and disorders.
This news release discusses historical information and includes forward-looking statements about Regeneron and its products, programs, finances, and business, all of which involve a number of risks and uncertainties, such as risks associated with preclinical and clinical development of our drug candidates, determinations by regulatory and administrative governmental authorities which delay or restrict our ability to continue to develop or commercialize our drug candidates, competing drugs that are superior to our product candidates, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any collaboration agreement, including our agreements with the sanofi-aventis Group and Bayer HealthCare, to be canceled or to terminate without any product success, risks associated with third party intellectual property, and other material risks. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission (SEC), including its Form 10-K for the year ended December 31, 2005 and its Form 10-Q for the quarter ended September 30, 2006. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise unless required by law.
Additional information about Regeneron and recent news releases are available on Regeneron's worldwide web site at www.regeneron.com
Contact:
Regeneron Pharmaceuticals, Inc.
Media Relations:
Kimberly Chen, 212-845-5634
kchen@biosector2.com
--------------------------------------------------------------------------------
Source: Regeneron Pharmaceuticals, Inc.
http://biz.yahoo.com/bw/061221/20061221005735.html?.v=1
Repros to Host Research and Development Day January 4, 2007
THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc. (NasdaqGM:RPRX)(PCX:RPRX) announced that it will host a Research and Development Day for the financial community beginning at 12:30pm Eastern Time on Thursday, January 4, 2007 in New York City. The event, which is by invitation only, will focus on Repros’ clinical drug candidates, Proellex™ and Androxal™. Scheduled speakers include:
Jay Goldberg, MD - Director of the Jefferson Fibroid Center at Thomas Jefferson University Hospital
Olga Ioffe, MD - Associate Professor of Pathology at the University of Maryland Medical Center
Alfred Poindexter, MD - Director of the Division of Contraceptive Research and Development at Baylor College of Medicine
Bruce Lessey, MD, PhD - Professor of Obstetrics and Gynecology at University of North Carolina at Chapel Hill
Elian Ratchev, MD, PhD - Head of the Department of Pregnancy Pathology at the Hospital for Active Treatment in Sofia, Bulgaria
Richard Spark, MD - Associate Clinical Professor of Medicine at Harvard Medical School
Leonard DeRogatis, PhD - Director of the Center for Sexual Medicine at Sheppard Pratt Health System
Jean Fourcroy, MD, PhD - Assistant Professor of Urology at the University of the Health Sciences, Walter Reed Army Hospital, and Director, Repros Therapeutics.
This event will be webcast live and subsequently archived for at least one month on the company's website http://www.reprosrx.com at the "Presentations" tab. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time.
About Repros Therapeutics Inc.
Repros is engaged in the development of pharmaceutical products that address conditions of the male and female reproductive systems. Proellex™, the Company’s lead compound, is a PRM (progesterone receptor modulator) currently being studied in a U.S. Phase 2 clinical trial for the treatment of uterine fibroids, a condition that affects numerous women of childbearing age in the U.S. and results in a significant number of hysterectomies each year. Proellex™ is also being studied in a European Phase 2 study for the treatment of endometriosis, a condition that affects approximately 5.5 million women in the U.S. and Canada. Androxal™, the Company’s other program in late clinical development, is designed to restore normal testosterone production by the testes and is being tested in a U.S. Phase 3 clinical trial for the treatment of testosterone deficiency in men.
For more information, please visit the Company's website at http://www.reprosrx.com.
http://home.businesswire.com/portal/site/repros/
[OT] reply to global warming.
See the Washington Post article from yesterday; link below. Humans aren't the only ones feeling the temperature warming, plants are too and it is changing the ecosystem composition, and allowing invasive species to flourish. Folks I know in Alaska are dealing with permafrost thawing issues which are causing real problems with buildings built on permafrost. The Alaska folks call permafrost essentially "frozen dirty water" which is now melting with homes on top due to warming temps!
http://www.washingtonpost.com/wp-dyn/content/article/2006/12/19/AR2006121901769.html
PRCS: Interesting. And it looks like they have $40 mil cash, so Glaxo is basically getting their assets for $15 mil. What a deal!